128 related articles for article (PubMed ID: 14674121)
1. [Significantly increased interleukin-1A and interleukin-1 soluble type II receptor levels in women with ovarian cancer].
Kondera-Anasz Z; Mielczarek-Palacz A; Switała J
Ginekol Pol; 2003 Sep; 74(9):761-6. PubMed ID: 14674121
[TBL] [Abstract][Full Text] [Related]
2. Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers.
Fujiwaki R; Hata T; Miyazaki K; Kawamura T; Inada K
Br J Obstet Gynaecol; 1997 Dec; 104(12):1407-8. PubMed ID: 9422021
[TBL] [Abstract][Full Text] [Related]
3. Concentrations of interleukin (IL)-1alpha, IL-1 soluble receptor type II (IL-1 sRII) and IL-1 receptor antagonist (IL-1 Ra) in the peritoneal fluid and serum of infertile women with endometriosis.
Kondera-Anasz Z; Sikora J; Mielczarek-Palacz A; Jońca M
Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):198-203. PubMed ID: 16046047
[TBL] [Abstract][Full Text] [Related]
4. [Serum cytokines in patients with ovarian cancer and benign ovarian cysts].
Nowak M; Szpakowski M; Malinowski A; Wieczorek A; Maciołek-Blewniewska G; Wilczyński JR; Szpakowski A; Wierzbicka E; Małafiej E; Oszukowski P
Ginekol Pol; 2001 Dec; 72(12A):1444-8. PubMed ID: 11883294
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of circulating tumor necrosis factor-alpha in patients with gynecological malignancies.
De Jaco P; Asselain B; Orlandi C; Fridman WH; Teillaud JL
Int J Cancer; 1991 May; 48(3):375-8. PubMed ID: 2040531
[TBL] [Abstract][Full Text] [Related]
6. Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden.
Santulli P; Even M; Chouzenoux S; Millischer AE; Borghese B; de Ziegler D; Batteux F; Chapron C
Hum Reprod; 2013 Aug; 28(8):2126-33. PubMed ID: 23739220
[TBL] [Abstract][Full Text] [Related]
7. Serum and peritoneal fluid concentrations of soluble human leukocyte antigen, tumor necrosis factor alpha and interleukin 10 in patients with selected ovarian pathologies.
Sipak-Szmigiel O; Włodarski P; Ronin-Walknowska E; Niedzielski A; Karakiewicz B; Słuczanowska-Głąbowska S; Laszczyńska M; Malinowski W
J Ovarian Res; 2017 Apr; 10(1):25. PubMed ID: 28376925
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
9. Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.
Daraï E; Detchev R; Hugol D; Quang NT
Hum Reprod; 2003 Aug; 18(8):1681-5. PubMed ID: 12871882
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors].
Peng XP; Li JD; Li MD; Ye XM; Yan WC
Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 receptor and ovarian cancer.
Owens OJ; Taggart C; Wilson R; Walker JJ; McKillop JH; Kennedy JH
Br J Cancer; 1993 Aug; 68(2):364-7. PubMed ID: 8347492
[TBL] [Abstract][Full Text] [Related]
12. The potential of serum levels of soluble tumour necrosis factor receptor I as a biochemical marker in cervical cancer.
Sheu BC; Lin HH; Chang DY; Ho HN; Huang SC
Br J Obstet Gynaecol; 1997 Nov; 104(11):1314-9. PubMed ID: 9386035
[TBL] [Abstract][Full Text] [Related]
13. [Serum levels of proinflammatory cytokines in women with uterine myomas].
Sikorski R; Kapeć E; Zaleska W
Ginekol Pol; 2001 Dec; 72(12A):1485-8. PubMed ID: 11883301
[TBL] [Abstract][Full Text] [Related]
14. Serum interleukin 1 in ovarian cancer patients.
Zeisler H; Tempfer C; Joura EA; Sliutz G; Koelbl H; Wagner O; Kainz C
Eur J Cancer; 1998 May; 34(6):931-3. PubMed ID: 9797710
[TBL] [Abstract][Full Text] [Related]
15. [Changes in calprotectin concentration--inflammation marker in serum of women with gynecological cancer].
Mielczarek-Palacz A; Sikora J; Kondera-Anasz Z; Nocoń M
Ginekol Pol; 2011 Nov; 82(11):822-6. PubMed ID: 22384614
[TBL] [Abstract][Full Text] [Related]
16. [Pregnancy-associated alpha 2-glycoprotein in patients with gynecologic cancer].
Sawada M; Matsui Y; Okudaira Y; Shimizu Y; Takayama K
Nihon Sanka Fujinka Gakkai Zasshi; 1983 Apr; 35(4):451-8. PubMed ID: 6854093
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum growth-regulated oncogene alpha (GROalpha) in patients with gynecological cancer.
Nishikawa R; Suzumori N; Nishiyama T; Nishikawa H; Arakawa A; Sugiura-Ogasawara M
Eur J Gynaecol Oncol; 2012; 33(2):138-41. PubMed ID: 22611950
[TBL] [Abstract][Full Text] [Related]
18. Haptoglobin and proteinase inhibitors in the blood serum of women with inflammatory, benign and neoplastic lesions of the ovary.
Warwas M; Gerber J; Pietkiewicz A
Neoplasma; 1986; 33(1):79-84. PubMed ID: 2421174
[TBL] [Abstract][Full Text] [Related]
19. Does vitamin D mediate inhibition of epithelial ovarian cancer by modulating cytokines?
Mohapatra S; Saxena A; Gandhi G; Koner BC; Singh T; Ray PC
Clin Transl Oncol; 2015 Aug; 17(8):590-5. PubMed ID: 25740667
[TBL] [Abstract][Full Text] [Related]
20. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
